Efficacy and Safety of Tenapanor on Hyperphosphatemia in Japanese Hemodialysis Patients: Results of a Randomized Phase 3 Trial

被引：0
|
作者：
Fukagawa, Masafumi [1 ]
Ikejiri, Kazuaki [2 ]
Kinoshita, Jun [2 ]
Nakanishi, Kaoru [2 ]
Akizawa, Tadao [3 ]
机构：
[1] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
[2] Kyowa Kirin Co Ltd, Tokyo, Japan
[3] Showa Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
TH-PO160
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial
    Ketteler, Markus
    Wiecek, Andrzej
    Rosenkranz, Alexander R.
    Pasch, Andreas
    Rekowski, Jan
    Hellmann, Burkhard
    Karus, Michael
    Ammer, Richard
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (03): : 594 - 604
  • [32] The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
    Block, Geoffrey A.
    Rosenbaum, David P.
    Yan, Andrew
    Greasley, Peter J.
    Chertow, Glenn M.
    Wolf, Myles
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (02) : 339 - 346
  • [33] A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)
    Pergola, Pablo E.
    Rosenbaum, David P.
    Yang, Yang
    Chertow, Glenn M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (06): : 1465 - 1473
  • [34] Randomized Controlled Trial of Bixalomer Versus Sevelamer Hydrochloride in Hemodialysis Patients With Hyperphosphatemia
    Akizawa, Tadao
    Origasa, Hideki
    Kameoka, Chisato
    Kaneko, Yuichiro
    Kawasaki, Shigenori
    THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 (02) : 122 - 131
  • [35] Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
    Zeng, Qian
    Zhong, Yuanlong
    Yu, Xiqiu
    RENAL FAILURE, 2023, 45 (01)
  • [36] Safety and efficacy of FosrenolTM in the long-term treatment of hyperphosphatemia in hemodialysis patients
    Finn, WF
    Joy, MS
    9TH ASIAN PACIFIC CONGRESS OF NEPHROLOGY, 2003, : 199 - 202
  • [37] Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
    Chey, William D.
    Lembo, Anthony J.
    Rosenbaum, David P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (05): : 763 - 774
  • [38] Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
    Sprague, Stuart M.
    Weiner, Daniel E.
    Tietjen, David P.
    Pergola, Pablo E.
    Fishbane, Steven
    Block, Geoffrey A.
    Silva, Arnold L.
    Fadem, Stephen Z.
    Lynn, Robert I.
    Fadda, George
    Pagliaro, Lynae
    Zhao, Suling
    Edelstein, Susan
    Spiegel, David M.
    Rosenbaum, David P.
    KIDNEY360, 2024, 5 (05): : 732 - 742
  • [39] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
  • [40] Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
    Nangaku, Masaomi
    Kondo, Kazuoki
    Ueta, Kiichiro
    Kokado, Yoshimasa
    Kaneko, Genki
    Matsuda, Hiroki
    Kawaguchi, Yutaka
    Komatsu, Yasuhiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (09) : 1731 - 1741
12345